Key result
PAH patients and clinicians prioritize personalized activity, symptoms, and well-being over traditional trial endpoints.
Why the study?
Knowledge regarding which outcomes are most meaningful to pulmonary arterial hypertension stakeholders is limited.
What outcomes are most meaningful to pulmonary arterial hypertension stakeholders when assessing treatment response?
What outcomes are most meaningful to pulmonary arterial hypertension stakeholders when assessing treatment response?
Personalized physical activity and psychosocial well-being are key treatment outcomes prioritized by patients and clinicians, underscoring the need to better incorporate patient-centered endpoints in PAH clinical trials.
Answers are grounded in this paper and cite their sources.
Current PAH endpoints may overlook patient-clinician priorities; leaves open validation of personalized measures for trials and care.
Knowledge of what outcomes are most meaningful to pulmonary arterial hypertension (PAH) stakeholders is limited. In this qualitative study, patients and clinicians endorsed personalized physical activity, symptoms, and psychosocial well-being as key outcomes to assess PAH treatment response, yet few are routinely measured in PAH clinical trials.
No takes yet. Share an insight, caveat, or question.
Auriemma et al. (2023) studied Pulmonary arterial hypertension (n=19). Qualitative semi-structured interviews on PAH treatment perspectives was evaluated on Perspectives on PAH treatment response and trial outcomes (qualitative themes). Patients and clinicians prioritized personalized physical activity tolerance, symptoms, and psychosocial well-being as key outcomes to assess PAH treatment response, contrasting with traditional clinical endpoints.
Synapse has enriched 10 related papers. Consider them for comparative context: